Movement Alert｜Natera Rises 5.5% in Regular Trading, Signatera Platform Secures Multiple Clinical Collaborations

Market Focus06-04

On June 4, Natera rose 5.5% in regular trading, trading at $224.995/share, with trading volume of approximately $47.03 million. The rally was driven by a series of positive clinical developments for the company's Signatera molecular residual disease (MRD) testing platform.

On the news front, Natera recently announced the enrollment of first patients in a study evaluating Signatera to guide treatment decisions in early-stage breast cancer. The study plans to recruit approximately 725 patients across 50 US sites, aiming to use MRD-guided testing to identify patients who may safely defer standard-of-care therapy, thereby reducing over-treatment associated with limited benefit and significant side effects.

Additionally, Diakonos Oncology selected Signatera to assess molecular response in patients with refractory melanoma enrolled in its DOC-RM phase I/II immunotherapy clinical trial. These consecutive partnerships further expand Signatera's clinical application in oncology and reinforce market confidence in the commercial outlook of Natera's core liquid biopsy platform.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1142150801?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 22:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142150801","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Natera Rises 5.5% in Regular Trading, Signatera Platform Secures Multiple Clinical Collaborations","media":"Market Focus","content":"<p><p>On June 4, Natera rose 5.5% in regular trading, trading at $224.995/share, with trading volume of approximately $47.03 million. The rally was driven by a series of positive clinical developments for the company's Signatera molecular residual disease (MRD) testing platform.</p><p>On the news front, Natera recently announced the enrollment of first patients in a study evaluating Signatera to guide treatment decisions in early-stage breast cancer. The study plans to recruit approximately 725 patients across 50 US sites, aiming to use MRD-guided testing to identify patients who may safely defer standard-of-care therapy, thereby reducing over-treatment associated with limited benefit and significant side effects.</p><p>Additionally, Diakonos Oncology selected Signatera to assess molecular response in patients with refractory melanoma enrolled in its DOC-RM phase I/II immunotherapy clinical trial. These consecutive partnerships further expand Signatera's clinical application in oncology and reinforce market confidence in the commercial outlook of Natera's core liquid biopsy platform.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Natera Rises 5.5% in Regular Trading, Signatera Platform Secures Multiple Clinical Collaborations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Natera Rises 5.5% in Regular Trading, Signatera Platform Secures Multiple Clinical Collaborations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-04 22:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 4, Natera rose 5.5% in regular trading, trading at $224.995/share, with trading volume of approximately $47.03 million. The rally was driven by a series of positive clinical developments for the company's Signatera molecular residual disease (MRD) testing platform.</p><p>On the news front, Natera recently announced the enrollment of first patients in a study evaluating Signatera to guide treatment decisions in early-stage breast cancer. The study plans to recruit approximately 725 patients across 50 US sites, aiming to use MRD-guided testing to identify patients who may safely defer standard-of-care therapy, thereby reducing over-treatment associated with limited benefit and significant side effects.</p><p>Additionally, Diakonos Oncology selected Signatera to assess molecular response in patients with refractory melanoma enrolled in its DOC-RM phase I/II immunotherapy clinical trial. These consecutive partnerships further expand Signatera's clinical application in oncology and reinforce market confidence in the commercial outlook of Natera's core liquid biopsy platform.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTRA","symbol_name":"Natera, Inc.","start_time":0,"source_url":"","article_id":"1142150801","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142150801","pubTimestamp":1780583798,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 4, Natera rose 5.5% in regular trading, trading at $224.995/share, with trading volume of approximately $47.03 million. The rally was driven by a series of positive clinical developments for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTRA":"Natera, Inc."},"translate_title":"动向预警|Natera常规交易涨5.5%Signatera平台获多项临床合作","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRA":1},"content_text":"On June 4, Natera rose 5.5% in regular trading, trading at $224.995/share, with trading volume of approximately $47.03 million. The rally was driven by a series of positive clinical developments for the company's Signatera molecular residual disease (MRD) testing platform.On the news front, Natera recently announced the enrollment of first patients in a study evaluating Signatera to guide treatment decisions in early-stage breast cancer. The study plans to recruit approximately 725 patients across 50 US sites, aiming to use MRD-guided testing to identify patients who may safely defer standard-of-care therapy, thereby reducing over-treatment associated with limited benefit and significant side effects.Additionally, Diakonos Oncology selected Signatera to assess molecular response in patients with refractory melanoma enrolled in its DOC-RM phase I/II immunotherapy clinical trial. These consecutive partnerships further expand Signatera's clinical application in oncology and reinforce market confidence in the commercial outlook of Natera's core liquid biopsy platform.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1142150801","isCrawlerRequest":true}